Sign inCreate account

Report workspace tools

NCT04936308ACTIVE_NOT_RECRUITINGanonymous

A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent

Sponsor

Source record

Janssen Research & Development, LLC

Phase

Source record

Phase 3B

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Guselkumab

Indication / condition

AI-normalized

Arthritis, Psoriatic

Intervention

Source record

Guselkumab, Placebo

Source & freshness

Source record

NCT ID

NCT04936308

Original source

ClinicalTrials.gov

Source last updated

May 08, 2026

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04936308

Title

A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent

Sponsor

Janssen Research & Development, LLC

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 3B

Condition raw

Arthritis, Psoriatic

Condition normalized

Arthritis, Psoriatic

Modality raw

Arthritis, Psoriatic

Modality normalized

monoclonal antibody

Target raw

Guselkumab

Target normalized

Guselkumab

Interventions

Guselkumab, Placebo

Public preview

Source record

This clinical trial evaluates the efficacy and safety of Guselkumab in patients with active psoriatic arthritis who have had an inadequate response or intolerance to one prior anti-TNF alpha agent. The study is sponsored by Janssen Research & Development, LLC and aims to establish Guselkumab as a viable treatment option in this patient population.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Who Had an Inadequate Response and/or Intolerance to One Prior Anti-Tumor Necrosis Factor Alpha Agent

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04936308

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 3B

Sponsor

Janssen Research & Development, LLC

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates the efficacy and safety of Guselkumab in patients with active psoriatic arthritis who have had an inadequate response or intolerance to one prior anti-TNF alpha agent. The study is sponsored by Janssen Research & Development, LLC and aims to establish Guselkumab as a viable treatment option in this patient population.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 08, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04936308

Indication

Arthritis, Psoriatic

Modality

monoclonal antibody

Target

Guselkumab

Intervention

Guselkumab, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.